Neurosense Therapeutics Ltd (NRSN) - Net Assets
Based on the latest financial reports, Neurosense Therapeutics Ltd (NRSN) has net assets worth $-519.00K USD as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.68 Million) and total liabilities ($2.20 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how resilient are Neurosense Therapeutics Ltd's assets to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-519.00K |
| % of Total Assets | -30.82% |
| Annual Growth Rate | 22.98% |
| 5-Year Change | 291.96% |
| 10-Year Change | N/A |
| Growth Volatility | 578.35 |
Neurosense Therapeutics Ltd - Net Assets Trend (2019–2024)
This chart illustrates how Neurosense Therapeutics Ltd's net assets have evolved over time, based on quarterly financial data. Also explore NRSN asset base for the complete picture of this company's asset base.
Annual Net Assets for Neurosense Therapeutics Ltd (2019–2024)
The table below shows the annual net assets of Neurosense Therapeutics Ltd from 2019 to 2024. For live valuation and market cap data, see market cap of Neurosense Therapeutics Ltd.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $2.58 Million | +246.10% |
| 2023-12-31 | $-1.77 Million | -131.46% |
| 2022-12-31 | $5.62 Million | -37.61% |
| 2021-12-31 | $9.01 Million | +1266.62% |
| 2020-12-31 | $659.00K | -28.21% |
| 2019-12-31 | $918.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Neurosense Therapeutics Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3508300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $39.24 Million | 1519.28% |
| Total Equity | $2.58 Million | 100.00% |
Neurosense Therapeutics Ltd Competitors by Market Cap
The table below lists competitors of Neurosense Therapeutics Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Impact Coatings publ AB
ST:IMPC
|
$26.50 Million |
|
Egeplast Ege Plastik Ticaret ve Sanayi AS
IS:EPLAS
|
$26.51 Million |
|
Lulu's Fashion Lounge Holdings Inc
NASDAQ:LVLU
|
$26.51 Million |
|
InfoBank Corporation
KQ:039290
|
$26.52 Million |
|
Strategic Metals Ltd
V:SMD
|
$26.49 Million |
|
Kurniamitra Duta Sentosa Tbk
JK:KMDS
|
$26.49 Million |
|
Green Critical Minerals Ltd
AU:GCM
|
$26.48 Million |
|
PLANETEL SPA
F:0A7
|
$26.48 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Neurosense Therapeutics Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -1,874,000 to 2,583,000, a change of 4,457,000.
- Net loss of 10,210,000 reduced equity.
- New share issuances of 11,304,000 increased equity.
- Other comprehensive income decreased equity by 24,362,000.
- Other factors increased equity by 27,725,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-10.21 Million | -395.28% |
| Share Issuances | $11.30 Million | +437.63% |
| Other Comprehensive Income | $-24.36 Million | -943.17% |
| Other Changes | $27.73 Million | +1073.36% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Neurosense Therapeutics Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.46x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 5.33x to 6.46x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $0.17 | $0.90 | x |
| 2020-12-31 | $0.12 | $0.90 | x |
| 2021-12-31 | $0.83 | $0.90 | x |
| 2022-12-31 | $0.49 | $0.90 | x |
| 2023-12-31 | $-0.14 | $0.90 | x |
| 2024-12-31 | $0.14 | $0.90 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Neurosense Therapeutics Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -395.28%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.77x
- Recent ROE (-395.28%) is below the historical average (-203.76%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -133.66% | 0.00% | 0.00x | 1.04x | $-1.32 Million |
| 2020 | -429.14% | 0.00% | 0.00x | 1.18x | $-2.89 Million |
| 2021 | -44.87% | 0.00% | 0.00x | 1.27x | $-4.94 Million |
| 2022 | -219.61% | 0.00% | 0.00x | 1.37x | $-12.90 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-9.92 Million |
| 2024 | -395.28% | 0.00% | 0.00x | 1.77x | $-10.47 Million |
Industry Comparison
This section compares Neurosense Therapeutics Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Neurosense Therapeutics Ltd (NRSN) | $-519.00K | -133.66% | N/A | $26.50 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Neurosense Therapeutics Ltd
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical… Read more